Case Report: Psoriatic Arthritis and Stem Cell Therapy - A Five-Year Follow-Up Report

Psoriatic arthritis (PsA) is a chronic inflammatory-immune mediated disease that can lead to debilitating musculoskeletal symptoms and, in severe cases, comorbidities such as osteoporosis, cardiovascular disease, and bowel inflammation. Traditional treatments, including NSAIDs, DMARDs, and biologics, offer symptom management but do not halt disease progression. Recent advances in regenerative medicine, particularly mesenchymal stem cell (MSC) therapy, have shown promise in addressing both inflammation and tissue regeneration. This case study evaluates the long-term outcomes of MSC therapy in a 68-year-old female patient with 25-year PsA history, and psoriatic skin lesions that covered 80% of her body. She received adipose-derived MSC treatment five years ago for debilitating arthritic joint pain and psoriasis. Initial responses were promising, with reduced pain, stiffness, and enhanced joint function. Five years post-treatment, the clinical observations on the patient report sustained improvements in mobility, minimal discomfort, and stable significant resolution of psoriatic skin lesions (from 80% to <5% body surface area). This case report highlights the potential of MSC therapy as a long-term treatment for PsA, offering promising outcomes in both joint function and skin manifestations, with a focus on the durability and stability of treatment effects over time.